We aim to become the global biotech company
based on proprietary technology.
R&D based company with mass cell culture technology and cell quality management technology
Patented in countries
leading new drug development market
Enter the global biotech market
with Proprietary technology
Intellectual Property
Cell2in is committed to protect our core technology by establishment of intellectual property in the field of cell therapy
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
Real-time Imaging Sensor for Measuring Cellular Thiol Levels | Korea | 10-1862581 | 2018. 05. 24 |
United States | 10.215.757B2 | 2019. 02. 26 | |
Korea | 10-1983803 | 2019. 05. 23 | |
United States | 10.620.215 | 2020. 04. 14 | |
Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Cellular Organelle and Manufacturing Method Thereof | Korea | 10-2133794 | 2020. 07. 08 |
Canada (application) | 3.072.434 | 2020. 02. 07 | |
Australia (application) | 2018320601 | 2020. 02. 19 | |
United States (application) | 16/640717 | 2020. 02. 20 | |
Europe (application) | 18848372.1 | 2020. 02. 21 | |
China (application) | 201880054675.0 | 2020. 02. 21 | |
India (application) | 202017007994 | 2020. 02. 25 | |
Japan (application) | 2020-511502 | 2020. 02. 19 | |
Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Endoplasmic Reticulum and a Method of Using It | Korea | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
FreSHtracer-based Application of the Genetic Profile of Separated Cells | PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
Composite for Treatment of Thrombocytopenia | Korea | 10-2021-0063975 | 2021. 05. 18 |
Gene Market for Evaluating the Characteristics of Stem Cells and the Use of the Same | Korea | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
---|---|---|---|
Method of Therapeutic Cell Quality Improvement Based on Real-time Glutathione Measurement | Korea | 10-2119714 | 2020. 06. 01 |
Europe (application) | 18883520.1 | 2020. 05. 27 | |
China (application) | 201880077266.2 | 2020. 05. 28 | |
Japan (application) | 2020-546264 | 2020. 05. 27 | |
United States (application) | 16/767985 | 2020. 05. 28 | |
Method of Therapeutic Cell Quality Measurement Based on Real-time Glutathione Measurement | Korea | 10-2145929 | 2020. 08. 12 |
United States (application) | 16/768014 | 2020. 05. 28 | |
Europe (application) | 18884812.1 | 2020. 05. 27 | |
China (application) | 201880077236.1 | 2020. 05. 28 | |
Japan (application) | 2020-546265 | 2020. 05. 27 |
Publication
Cell2in has continuously published its research results through famous academic societies and journals.
Development Technology and Hematopoietic Progenitor Cells : K. Kim et al., 3,2’-Dihydroxyflavone Improves the Proliferation and Survival of Human Pluripotent Stem Cells and Their Differentiation into Hematopoietic Progenitor Cells, J. Clin. Med. (2020), 9, 669
Ecient maintenance of the undierentiated status of human pluripotent stem cells
(hiPSCs) is crucial for producing cells with improved proliferation, survival and dierentiation,
which can be successfully used for stem cell research and therapy. Here, we generated iPSCs
from healthy donor peripheral blood mononuclear cells (PBMCs) and analyzed the proliferation
and dierentiation capacities of the generated iPSCs using single cell NGS-based 24-chromosome
aneuploidy screening and RNA sequencing. In addition, we screened various natural compounds
for molecules that could enhance the proliferation and dierentiation potential of hiPSCs. Among
the tested compounds, 3,20-dihydroxyflavone (3,20-DHF) significantly increased cell proliferation
and expression of naïve stemness markers and decreased the dissociation-induced apoptosis
of hiPSCs. Of note, 3,20-DHF-treated hiPSCs showed upregulation of intracellular glutathione
(GSH) and an increase in the percentage of GSH-high cells in an analysis with a FreSHtracer
system. Interestingly, culture of the 3,20-DHF-treated hiPSCs in dierentiation media enhanced their
mesodermal dierentiation and dierentiation into CD34+ CD45+ hematopoietic progenitor cells
(HPC) and natural killer cells (NK) cells. Taken together, our results demonstrate that the natural
compound 3,20-DHF can improve the proliferation and dierentiation capacities of hiPSCs and
increase the eciency of HPC and NK cell production from hiPSCs.
(hiPSCs) is crucial for producing cells with improved proliferation, survival and dierentiation,
which can be successfully used for stem cell research and therapy. Here, we generated iPSCs
from healthy donor peripheral blood mononuclear cells (PBMCs) and analyzed the proliferation
and dierentiation capacities of the generated iPSCs using single cell NGS-based 24-chromosome
aneuploidy screening and RNA sequencing. In addition, we screened various natural compounds
for molecules that could enhance the proliferation and dierentiation potential of hiPSCs. Among
the tested compounds, 3,20-dihydroxyflavone (3,20-DHF) significantly increased cell proliferation
and expression of naïve stemness markers and decreased the dissociation-induced apoptosis
of hiPSCs. Of note, 3,20-DHF-treated hiPSCs showed upregulation of intracellular glutathione
(GSH) and an increase in the percentage of GSH-high cells in an analysis with a FreSHtracer
system. Interestingly, culture of the 3,20-DHF-treated hiPSCs in dierentiation media enhanced their
mesodermal dierentiation and dierentiation into CD34+ CD45+ hematopoietic progenitor cells
(HPC) and natural killer cells (NK) cells. Taken together, our results demonstrate that the natural
compound 3,20-DHF can improve the proliferation and dierentiation capacities of hiPSCs and
increase the eciency of HPC and NK cell production from hiPSCs.